From Name:
From Email:
To Name:
To Email:

Optional Message:


Cetuximab benefits patients with oropharyngeal cancer, regardless of HPV, p16 status

from Healio

The addition of cetuximab to radiotherapy appeared to improve clinical outcomes for patients with locoregionally advanced oropharyngeal cancer, regardless of HPV or p16 status, according to a subgroup analysis of a randomized trial. Further, patients with p16-positive oropharyngeal cancer achieved longer OS than p16-negative patients regardless of cetuximab (Erbitux, Lilly) exposure, results showed. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063